Zaltrap Injection (Ziv-aflibercept)
Zaltrap Injection is a crucial cancer medication utilized in the treatment of adults diagnosed with metastatic colorectal cancer. This specific type of cancer refers to cancer originating in the large bowel that has subsequently spread to other regions of the body. Zaltrap is prescribed in instances where previous treatments involving medications such as oxaliplatin have proven ineffective or when the cancer has progressed. It is typically administered in conjunction with FOLFIRI, a therapeutic regimen comprising irinotecan, 5-fluorouracil, and folinic acid. The primary active ingredient in Zaltrap is aflibercept.
Administration and Dosage
The administration of Zaltrap necessitates a prescription and should be overseen by a qualified healthcare professional experienced in managing cancer treatments. It is delivered intravenously over one hour, typically at a dosage of 4 mg per kilogram of body weight. This infusion is then followed by the FOLFIRI treatment. The treatment cycle recurs every two weeks until the disease progresses or until the patient is unable to tolerate the treatment. In cases where patients experience certain adverse effects, treatment may need to be halted, delayed, or the dosage adjusted accordingly.
Mechanism of Action
Zaltrap, or aflibercept, functions as a protein that binds to vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF). Both of these are circulating substances responsible for promoting blood vessel growth. By intercepting VEGF and PlGF, aflibercept impedes their functionality. Consequently, cancer cells are unable to establish their blood supply, thereby depriving them of essential oxygen and nutrients. This disruption ultimately slows down tumor growth.
Benefits and Risks
While Zaltrap is associated with notable side effects, some of which may be severe enough to warrant discontinuation of treatment. Extensive studies have demonstrated significant advantages in prolonging the lifespan of patients who have previously undergone ineffective treatments. Despite the risks, regulatory bodies such as the European Medicines Agency have determined that the benefits of Zaltrap outweigh its potential drawbacks, recommending its approval for use across the European Union.
Reviews
There are no reviews yet.